SOURCE: The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine

December 12, 2013 09:00 ET

The Alliance for Regenerative Medicine Announces Fourth Annual State of the Industry Briefing

Event takes place on Monday, January 13, 2014 in San Francisco

WASHINGTON, DC--(Marketwired - Dec 12, 2013) - The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine community, today announced that the fourth annual State of the Industry Briefing will take place on Monday, January 13, 2014 in San Francisco.

During the Briefing, leading experts in the field will discuss key clinical data inflection points expected in 2014 as well as a retrospective look at the sector's major recent financings. Top executives will discuss what this activity means for the industry's growth potential and the impact it will have on investment, partnering, and M&A. A partial speaker list includes:
Robert Brenner, President & CEO, AlloCure
Chris Calhoun, CEO, Cytori Therapeutics
James Douglas, Managing Director, Piper Jaffray
Jason Kolbert, Managing Director of Biotechnology, Maxim Group
Geoff MacKay, President & CEO, Organogenesis Inc.
Keith Murphy, Chairman & CEO, Organovo
Marc Penn, Chief Medical Officer, Juventas Therapeutics
Eliseo Salinas, Executive Vice President & Head of R&D, StemCells, Inc.
Michael Schuster, Founding Executive & Head of Global Therapeutic Products, Mesoblast
Jeffrey Walsh, Chief Operating Officer, bluebird bio
Additional speakers and event details will be forthcoming as the session draws nearer.

The briefing will take place at the Parc 55 Wyndham in San Francisco from 8:00 a.m. to 9:55 a.m.

"Regenerative medicine companies raised more than $1.3 billion dollars during 2013, providing the sector with a significant boost in funding, a trend we hope to see continue in 2014," said Geoff MacKay, President & Chief Executive Officer of Organogenesis Inc., and Chairman of ARM. "The number of late stage clinical milestones expected during 2014 should help to keep the momentum going, and with successful outcomes will lead to new, lifesaving therapies for patients."

This event was developed by the Alliance for Regenerative Medicine (ARM), and will be held as part of the Biotech Showcase 2014 conference taking place at the Parc 55 Wyndham in San Francisco from 8:00 a.m. to 9:55 a.m. This Briefing is free and open to the public, however, RSVP is required. Attendance at the Regenerative Medicine State of the Industry Briefing does not require paid registration for the Biotech Showcase. To learn more and to RSVP, please visit http://alliancerm.org/event/regenerative-medicine-state-industry-briefing

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 145 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit www.alliancerm.org.

Contact Information

  • Media Contact:
    Michelle Linn
    Linnden Communications
    Phone: 508-362-3087